This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chapman, S. W.
Right arrow Articles by Sullivan, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chapman, S. W.
Right arrow Articles by Sullivan, D. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1998, p. 978-980, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Susceptibilities of Clinical and Laboratory Isolates of Blastomyces dermatitidis to Ketoconazole, Itraconazole, and Fluconazole

Stanley W. Chapman,1,2,* P. David Rogers,2,3 Michael G. Rinaldi,4 and Donna C. Sullivan1,2

Division of Infectious Diseases1 and Department of Microbiology,2 School of Medicine, and Department of Clinical Pharmacy Practice, School of Pharmacy,3 University of Mississippi Medical Center, Jackson, Mississippi 39216-4505, and Department of Pathology, Fungus Testing Laboratory, School of Medicine, University of Texas Health Science Center, San Antonio, Texas 78284-77504

Received 8 September 1997/Returned for modification 27 October 1997/Accepted 28 January 1998

Eighteen isolates of Blastomyces dermatitidis were evaluated for their in vitro susceptibilities to ketoconazole, itraconazole, and fluconazole. The MIC ranges were 0.1 to 0.4 µg/ml for ketoconazole, <= 0.018 to 0.07 µg/ml for itraconazole, and 2.5 to 4.0 µg/ml for fluconazole. The ranges for the minimal lethal concentrations were 0.2 to 0.8 µg/ml for ketoconazole, <= 0.018 to 0.07 µg/ml for itraconazole, and 10 to 40 µg/ml for fluconazole. Itraconazole was the most active agent against B. dermatitidis in vitro, while fluconazole was the least active. These results correlate with the clinical efficacies noted to date with doses of these agents used to treat blastomycosis.

* Corresponding author. Mailing address: Division of Infectious Diseases, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216-4505. Phone: (601) 984-5560. Fax: (601) 984-5565. E-mail: schapman{at}umsmed.edu.

Antimicrobial Agents and Chemotherapy, April 1998, p. 978-980, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Friedman, R., Henson, T., Skinner, R. (2002). Pustular Eruption. Arch Dermatol 138: 1371-1376 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»